ICON Named Best Contract Research Organisation in Latest String of Industry Awards
07 Dezembro 2021 - 9:00AM
Business Wire
ICON continues to be recognised by peers, employees, and
organisations around the globe
ICON plc, (NASDAQ: ICLR) a global provider of drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device, and government organisations, is
proud to announce it was named the “Best Contract Research
Organisation” of 2021 during the 17th Annual Scrip Awards ceremony
on 2 December.
Presented by Pharma Intelligence, a premier source of
information for the global pharmaceutical and biomedical industry,
the Best Contract Research Organisation (CRO) Award acknowledges
the critical role that CROs play in drug development. ICON was
selected as winner of this top award by a distinguished panel of
life science industry executives for the capabilities and strengths
the company offers to partners, the ability to deliver results and
exceed sponsor expectations, innovations, improving quality of
data, timelines, and transparency, and streamlining data collection
and reporting.
“It is an honour to be recognised as the Best CRO at this year’s
Scrip Awards,” said ICON CEO Steve Cutler. “All the credit in
earning this prestigious award belongs to our employees who are
passionate and committed to improving and saving lives. This
recognition reflects that their vital work is appreciated by
customers and held in high esteem throughout the industry. We join
our global team in celebrating this achievement.”
ICON previously won the SCRIP Best CRO Award in 2019 and 2017.
This latest recognition as the Best Contract Research Organisation
continues ICON’s winning streak of awards and accolades this
year.
It comes on the heels of ICON being named one of the World’s
Best Employers for 2021 by global media company Forbes. This
recognition is based entirely on employees’ on-the-job experiences
and firsthand feedback.
Forbes – well-known and respected for its business lists and
rankings – teamed with market research company Statista to identify
the companies most liked by employees for its annual ranking of the
world’s best employers. ICON represented the only CRO to make the
list in a crowded field of more than 30 companies in the Drugs and
Biotechnology category.
Earlier in the year, ICON was also ranked in Forbes’ list of
2021 Best Employers for Diversity. In compiling this list,
50,000 U.S. employees working for businesses with at least 1,000
employees participated in an anonymous survey. ICON was recognised
based on evaluations from its employees on criteria such as age,
gender, ethnicity, disability and sexual orientation equality, as
well as general workplace diversity.
In November, ICON was named the Best Irish Company in
France by the France Ireland Chamber of Commerce and
NetworkIrlande as part of their annual Ireland France Business
Awards. This business award is recognition of ICON’s commitment to
growth in the French market, its CSR, sustainability and employee
engagement and retention strategies. ICON has operated in France
for more than 22 years, conducting multi-country clinical studies
and other services across various therapeutic areas on behalf of
customers. The acquisition of PRA Health Sciences by ICON in 2021
has almost doubled ICON’s workforce in France.
In October, ICON was named Clinical Research Company of the
Year in PharmaTimes’ Clinical Researcher of the Year 2021 –
Americas competition. Several ICON employees were also recognised
with awards in both individual and team categories from amongst a
crowded field of industry leaders. ICON also had an impressive
showing in Pharma Times’ International Clinical Researcher of
the Year 2021 competition with employees earning wins in
numerous categories. These rigorous, real-world challenges attract
entrants from all over the world.
In April, ICON scored wins in multiple categories in the 2021
CRO Leadership Awards from Life Science Leader magazine. ICON
received 2021 CRO Leadership Awards in the five categories, each
further divided into three groups – Big Pharma, Small Pharma, and
Overall. In two categories, ICON earned awards in both the Big
Pharma and Overall groups. Life Science Leader partners with
Industry Standard Research (ISR) to determine the award recipients,
assessing 60 contract research organisations on over 20 performance
metrics in ISR’s annual CRO Quality Benchmarking survey.
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards.
About ICON plc
ICON is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced development and
commercialisation services to pharmaceutical, biotechnology,
medical device and government and public health organisations. We
develop new innovations, drive emerging therapies forward and
improve patient lives. With headquarters in Dublin, Ireland, ICON
operates from 136 locations in 46 countries and has approximately
37,960 employees as of September 30, 2021. For more information,
visit www.iconplc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211207005249/en/
Media: Laurie Hurst Sr Director, Public Relations &
Communications, ICON plc +1 919-274-3189
Laurie.Hurst@iconplc.com
Weber Shandwick (PR adviser) Lisa Henry (GMT time zone) +447785
458203 lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024